• May 22, 2013
    MADISON, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) announced it intends to file a Registration Statement on Form S-4 with the Securities and Exchange Commission (SEC) today in connection with the proposed exchange offer announced by Pfizer Inc. (NYSE: PFE). As part of the offer, Pfizer shareholders will be able to exchange all, some or none of their shares of Pfizer common stock for shares of Zoetis common stock. Pfizer currently holds approximately 80% of themore...
  • April 30, 2013
    MADISON, N.J.--(BUSINESS WIRE)--ZoetisTM (NYSE: ZTS), formerly the animal health business of Pfizer Inc., today reported its financial results for the first quarter of 2013. The company reported revenues of $1.09 billion for the first quarter, an increase of 4% from the first quarter of 2012. Revenues reflected an operational2 increase of 5%, with foreign currency having a negative impact of 1%. Net income for the first quarter of 2013 was $140 million, or $0.28 permore...
  • March 28, 2013
    MADISON, N.J.--(BUSINESS WIRE)--The Board of Directors of ZoetisTM (NYSE: ZTS), formerly the animal health business of Pfizer Inc., has declared a second-quarter dividend payable to holders of the company’s Class A common stock and Class B common stock of $0.065 per share. The dividend is to be paid on June 6, 2013, to holders of record on May 1, 2013. About Zoetis Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customersmore...
  • March 26, 2013
    MADISON, N.J.--(BUSINESS WIRE)--ZoetisTM (NYSE: ZTS), formerly the animal health business of Pfizer Inc., will host a webcast and conference call at 8:30 a.m. (EDT) on Tuesday, April 30, 2013. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Rick Passov will review first-quarter 2013 financial results, discuss 2013 financial guidance, and respond to questions from financial analysts during the call. Investors and themore...
  • March 22, 2013
    Zoetis, formerly Pfizer Animal Health, announces the return of the Cattle Call grant program and is accepting research proposals for improving cattle reproduction or developing models for managing cattle pain. The Cattle Call supports the development of new products and services that improve the health and productivity of beef and dairy cattle. In 2013, Zoetis will fund one or more researchers with a grant of up to $150,000, withmore...
  • February 6, 2013
    MADISON, N.J.--(BUSINESS WIRE)--ZoetisTM (NYSE:ZTS), formerly the animal health business unit of Pfizer Inc., today announced the closing of its previously announced initial public offering. The offering of 99,015,000 shares of its Class A common stock included 12,915,000 shares of Class A common stock that were sold pursuant to the underwriters’ option to purchase additional shares, which was exercised in full prior to the closing.Zoetis did not receive any of the proceeds of the offering. Following the completion of themore...
  • January 31, 2013
    MADISON, N.J.--ZoetisTM, formerly the animal health business unit of Pfizer Inc., today announced the pricing of its initial public offering of 86,100,000 shares of its Class A common stock at $26 per share. The shares are expected to begin trading tomorrow, Feb. 1, on the New York Stock Exchange under the symbol “ZTS.” Zoetis will not receive any of the proceeds of the offering. Following the completion of the initial public offering,more...
  • August 13, 2012
    NEW YORK--Pfizer Inc. (NYSE: PFE) today announced that its subsidiary, Zoetis™ Inc. (zō-EH-tis), filed a registration statement with the U.S. Securities and Exchange Commission for a potential initial public offering (IPO) of Class A common stock. The offering is expected to represent an ownership stake of up to 20 percent. Prior to completion of the offering, which is targeted for the first half of 2013, Pfizer will transfer its animal healthmore...
  • June 7, 2012
    NEW YORK--Pfizer Inc. (NYSE: PFE) today announced the next steps in the strategic alternatives review process for the company's Animal Health business. Preparations are underway to file a registration statement in the U.S. for a potential initial public offering (IPO) of a minority ownership stake in the new company. Pfizer expects to provide details regarding the proposed transaction as part of its 2012 second quarter earnings announcement.more...
  • April 13, 2012
    PARIS, France--Four European academic research groups, together with Pfizer Animal Health, have forged a new research consortium to combat uterine disease - a problem that costs the EU dairy industry about €1.4billion annually. Called the IPUD research project (Integrated systems approach for Preventing Uterine Disease in dairy cattle), the collaboration involves academic research groups at Swansea University, the University ofmore...